0001209191-20-020304.txt : 20200319 0001209191-20-020304.hdr.sgml : 20200319 20200319170429 ACCESSION NUMBER: 0001209191-20-020304 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200317 FILED AS OF DATE: 20200319 DATE AS OF CHANGE: 20200319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Todd CENTRAL INDEX KEY: 0001473930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 20729216 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-17 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001473930 Foley Todd C/O MPM ASSET MANAGEMENT 450 KENDALL STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2020-03-17 4 S 0 9653 15.12 D 2383844 I See Footnote Common Stock 2020-03-18 4 S 0 12781 15.14 D 2371063 I See Footnote Common Stock 2020-03-19 4 S 0 8200 15.07 D 2362863 I See Footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The shares were sold as follows: 9,292 by MPM BioVentures V, L.P. ("BV V") and 361 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.41. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Shares are held as follows: 2,294,700 by BV V and 89,144 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Shares were sold as follows: 12,296 by BV V and 485 by AM BV5. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.61. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Shares are held as follows: 2,282,404 by BV V and 88,659 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Shares were sold as follows: 7,889 by BV V and 311 by AM BV5. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.47. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Shares are held as follows: 2,274,575 by BV V and 88,348 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. /s/ Todd Foley 2020-03-19